
Other Secondary Outcomes

blood cell transfusion-dependent, AML, disease progression, death, neutropenia
NEUTROPENIA
Patient-reported outcomes (Data Supplement [Tables S4-S7]) and pharmacokinetic analysis (Data Supplement [Figs S6A, S6B, S7A, and S7B, and Table S8]) are presented in the Data Supplement. In the eltrombopag arm, 66 patients were anemic at baseline: 18 (27.3%) achieved a durable and significant erythroid improvement and 11 of 30 (36.7%) red blood cell transfusion-dependent patients became transfusion-independent. Only nine (50%) were PLT responders. In addition, 27 patients in the eltrombopag arm had grade 3-4 neutropenia (<1.0 × 10Median LFS, combined outcome (AML, disease progression, and death), and OS were not reached in the whole group.